A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a new study finds.

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented ... Naples "Federico II" gave the glucagon-like peptide-1 ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds Written by David Mills on June 20, 2025 — Fact checked by Jill Seladi-Schulman, Ph.D.